LT4114390T - Pacientų, turinčių gla geno mutaciją, fabri ligos gydymo būdai - Google Patents

Pacientų, turinčių gla geno mutaciją, fabri ligos gydymo būdai

Info

Publication number
LT4114390T
LT4114390T LTEPPCT/US2021/020984T LTUS2021020984T LT4114390T LT 4114390 T LT4114390 T LT 4114390T LT US2021020984 T LTUS2021020984 T LT US2021020984T LT 4114390 T LT4114390 T LT 4114390T
Authority
LT
Lithuania
Prior art keywords
patients
treatment methods
gene mutation
gla gene
fabri
Prior art date
Application number
LTEPPCT/US2021/020984T
Other languages
English (en)
Lithuanian (lt)
Inventor
Elfrida Benjamin
Xiaoyang Wu
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75267607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4114390(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT4114390T publication Critical patent/LT4114390T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LTEPPCT/US2021/020984T 2020-03-06 2021-03-05 Pacientų, turinčių gla geno mutaciją, fabri ligos gydymo būdai LT4114390T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986297P 2020-03-06 2020-03-06
PCT/US2021/020984 WO2021178737A1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene

Publications (1)

Publication Number Publication Date
LT4114390T true LT4114390T (lt) 2025-02-10

Family

ID=75267607

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2021/020984T LT4114390T (lt) 2020-03-06 2021-03-05 Pacientų, turinčių gla geno mutaciją, fabri ligos gydymo būdai

Country Status (25)

Country Link
US (1) US20230136297A1 (cg-RX-API-DMAC7.html)
EP (2) EP4527454A3 (cg-RX-API-DMAC7.html)
JP (2) JP7749572B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152547A (cg-RX-API-DMAC7.html)
CN (1) CN115427040A (cg-RX-API-DMAC7.html)
AR (1) AR122390A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021230371A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170718A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002423A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114390T3 (cg-RX-API-DMAC7.html)
ES (1) ES3013813T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250179T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070116T2 (cg-RX-API-DMAC7.html)
IL (1) IL296221A (cg-RX-API-DMAC7.html)
LT (1) LT4114390T (cg-RX-API-DMAC7.html)
MX (1) MX2022011030A (cg-RX-API-DMAC7.html)
PL (1) PL4114390T3 (cg-RX-API-DMAC7.html)
PT (1) PT4114390T (cg-RX-API-DMAC7.html)
RS (1) RS66530B1 (cg-RX-API-DMAC7.html)
SI (1) SI4114390T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500072T1 (cg-RX-API-DMAC7.html)
TW (1) TW202146020A (cg-RX-API-DMAC7.html)
WO (1) WO2021178737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US11034946B2 (en) * 2017-10-05 2021-06-15 Research Foundation Of The City University Of New York Glycosylation independent proteins

Also Published As

Publication number Publication date
HUE070116T2 (hu) 2025-05-28
PL4114390T3 (pl) 2025-06-23
TW202146020A (zh) 2021-12-16
RS66530B1 (sr) 2025-03-31
ES3013813T3 (en) 2025-04-15
SI4114390T1 (sl) 2025-03-31
HRP20250179T1 (hr) 2025-04-11
EP4527454A2 (en) 2025-03-26
US20230136297A1 (en) 2023-05-04
AU2021230371A1 (en) 2022-09-29
JP2026016375A (ja) 2026-02-03
AR122390A1 (es) 2022-09-07
EP4114390B1 (en) 2024-12-04
SMT202500072T1 (it) 2025-03-12
EP4114390A1 (en) 2023-01-11
DK4114390T3 (da) 2025-02-24
CN115427040A (zh) 2022-12-02
JP7749572B2 (ja) 2025-10-06
KR20220152547A (ko) 2022-11-16
PT4114390T (pt) 2025-02-24
FI4114390T3 (fi) 2025-03-07
MX2022011030A (es) 2022-12-13
CL2022002423A1 (es) 2023-05-05
EP4527454A3 (en) 2025-09-24
WO2021178737A1 (en) 2021-09-10
BR112022017881A2 (pt) 2022-12-06
JP2023516753A (ja) 2023-04-20
IL296221A (en) 2022-11-01
CA3170718A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
LT3840753T (lt) Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
IL290365A (en) Methods for treating Fabry disease in patients with a mutation in the gla gene
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
MX2023004922A (es) Inhibidores del factor de crecimiento endotelial vascular (vegf) para usarse en el tratamiento de degeneracion macular humeda.
CY1113580T1 (el) Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
BR112014011733A2 (pt) suspensões autoclaváveis da forma 2 de ciclosporina a
DK4114390T3 (da) Fremgangsmåder til behandling af fabrys sygdom hos patienter med en mutation i gla-genet
MX2009013709A (es) (oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
EP2148934A4 (en) MATRIX MARKER MODEL AND METHOD FOR THE TEST AND TREATMENT OF ARTHRITIS AND RELATED DISEASES
Su et al. B110 UPPER AIRWAY AND RESPIRATORY CONTROL DURING SLEEP: The Influence Of Chronic Intermittent Hypoxia On The Corticomotor Cortex Of Genioglossus In Rats
Meir et al. Bacteremia and “Endotipsitis” following transjugular intrahepatic portosystemic shunting
李晓武 The clinical characteristics and prognostic analysis of gastric mucosa-associated lymphoid tissue lymphoma of 103 cases
RU2014143385A (ru) Способы воздействия на экспрессию гена TP53
UA97833U (uk) Спосіб прогнозування зрощення перелому
UA96918U (uk) Спосіб прогнозування зрощення перелому
UA96523U (uk) Спосіб прогнозування зрощення перелому
UA96986U (uk) Спосіб прогнозування зрощення перелому
RU2014142752A (ru) Способы воздействия на экспрессию гена лактазы
UA107740U (uk) Спосіб прогнозування зрощення перелому
RU2014142756A (ru) Способы воздействия на экспрессию гена D4DR
RU2014144701A (ru) Способы воздействия на экспрессию гена TER1
HK1251615A1 (zh) 常染色体显性疾病的基因治疗
UA107739U (uk) Спосіб прогнозування зрощення перелому
TH149190B (th) การแสดงเอกลักษณ์ของการกลายพันธุ์ lkb1 ในรูปมาร์คเกอร์ทางชีวภาพที่สามารถ ทำนายความไวรับต่อสารยับยั้ง tor ไคเนส